Table 1.

Demographics and patient characteristics

Age (mo) at start of etoposide, median (range)	20 (0-282)
Gender, n (%)
Male	52 (58)
Female	37 (42)
Active CNS disease at diagnosis, n (%)	22 (25)
Genetics, n (%)
Positive	44 (49)
Indeterminant/ambiguous	15 (17)
Negative	29 (33)
Not obtained	1 (1)
Underlying rheumatologic diagnosis or MAS, n (%)	9 (10)
Received BMT, n (%)	55 (62)
Days to BMT, median (range)	124 (56-2120)
Surviving >1 y without BMT	22 (25)
Salvage therapy/reintensification, n (%)
Within 100-d study period	28 (31)
Within 1 y of treatment initiation	37 (42)
Pre-BMT mortality (survived to BMT or 1 y), n (%)
Survived	77 (87)
Died	12 (13)
OS, n (%)
Survived	65 (73)
Died	24 (27)

CNS, central nervous system; MAS, macrophage activation syndrome.